title: Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.
abstract: BACKGROUND
  The levels of several cytokines and chemokines are elevated in various liver diseases, especially in fulminant hepatic failure (FHF). Activated macrophages may have a role in the production of these immune modulators. CD163 is a member of a scavenger receptor family and is expressed mainly on activated macrophages, and a soluble form of CD163 (sCD163) is released from activated macrophages. The aim of this study was to assess sCD163 levels in patients with FHF and to evaluate their clinical significance.
  
  
  METHODS
  The levels of sCD163 in the sera were measured in 21 patients with FHF, 17 patients with acute hepatitis (AH), 22 patients with chronic hepatitis (CH), and 14 normal healthy controls (NC), by an enzyme-linked immunosorbent assay. The levels of sCD163 were observed serially in patients with FHF and AH.
  
  
  RESULTS
  The levels of sCD163 in the sera from patients with FHF were significantly higher than those in patients with AH and CH and the NC group (P < 0.0001). There was a good correlation between serum levels of sCD163 and prothrombin time (r = -0.677; P < 0.0001). A kinetic study revealed that the levels of sCD163 decreased in patients with AH and in survivors of FHF, whereas the levels of sCD163 progressively increased in nonsurvivors of FHF.
  
  
  CONCLUSIONS
  This study shows that the products of activated macrophages may be involved in the pathogenesis of FHF. This study also inspires optimism that sCD163 may possess prognostic importance in FHF.
authors.affiliation: The Third Department of Internal Medicine, Ehime University School of Medicine, Ehime 791-0295, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hiraoka
authors.forename: Norio
authors.initials: N
authors.lastname: Horiike
authors.forename: Sk Md Fazle
authors.initials: SM
authors.lastname: Akbar
authors.forename: Kojiro
authors.initials: K
authors.lastname: Michitaka
authors.forename: Takami
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Morikazu
authors.initials: M
authors.lastname: Onji
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism*; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism*; D015415:Biomarkers / Q000097:blood; D002648:Child; D005260:Female; D006521:Hepatitis, Chronic / Q000378:metabolism; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008107:Liver Diseases / Q000378:metabolism*; D017114:Liver Failure, Acute / Q000378:metabolism; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D011517:Prothrombin Time; D011956:Receptors, Cell Surface / Q000378:metabolism*; D013223:Statistics as Topic; D013997:Time Factors; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers; D000098902:CD163 Antigen; D011956:Receptors, Cell Surface